GlassScriptPhysician profile
Louis V Crenshaw
NPI 1114994746
$6,910.87
in general payments reported to CMS, 2019-2025
26 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $1,176 · 2023: $1,654 · 2024: $1,659 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,088.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,280.46 | 2021-2025 | |
| Axsome Therapeutics, INC. | $572.32 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $496.26 | 2021-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $404.90 | 2021-2025 | Caplyta |
| Abbott Laboratories | $122.64 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $122.42 | 2023-2025 | |
| Glaxosmithkline, LLC. | $108.33 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $99.66 | 2023-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $83.67 | 2024-2025 | Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $77.04 | 2021 | |
| Alkermes, INC. | $64.02 | 2023-2024 | Aristada, Lybalvi |
| Lilly USA, LLC | $60.82 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $57.61 | 2021-2025 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $51.83 | 2023-2025 | Quviviq, Quviviq |
| Amgen INC. | $45.01 | 2023-2024 | Otezla, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $41.52 | 2025 | Ibsrela |
| Exact Sciences Corporation | $38.42 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $31.94 | 2024 | Uzedy |
| Biohaven Pharmaceutical Holding Company LTD. | $24.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.20 | 2022 | |
| Evofem Biosciences, INC. | $21.13 | 2022 | |
| Lundbeck LLC | $18.10 | 2022 | |
| Neurocrine Biosciences, INC. | $17.86 | 2022 | |
| Insulet Corporation | $17.06 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $16.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Crenshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.